In this issue:
- Long-term ustekinumab and TNF inhibitors in PsA
- Survival in RA-associated ILD
- Deucravacitinib for SLE
- Outcome score for SpA-related uveitis
- Methotrexate ± leflunomide in PsA
- ILD in biologic/targeted synthetic DMARD-treated RA
- Withholding methotrexate for 1 vs. 2 weeks for influenza vaccination
- COVID-19 outcomes among systemic rheumatic diseases
- Breakthrough SARS-COV-2 during rituximab for rheumatic/ musculoskeletal diseases
- Leflunomide for managing large-vessel vasculitis
Please login below to download this issue (PDF)